3Daughters
- Company typePrivate
- Founded2022
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
3Daughters firmographics
Firmographics- Name
- 3Daughters
- Legal name
- 3Daughters, Inc.
- Website
- https://3daughtershealth.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
3Daughters industry classification
Industry- Product category
- Contraceptive Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy) (HLAKAJAF)
Keywords
Where 3Daughters is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
3Daughters business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- IUD Product Sales: 3Daughters plans to generate revenue through the sale of its 3D-001 frameless IUD product combined with the Slider inserter/retriever system. The company is a clinical-stage development company that will ultimately commercialize its medical device through healthcare providers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | No tiered pricing model disclosed |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
3Daughters product offering
Product offeringCore offering
3Daughters is developing an integrated intrauterine device (IUD) system for long-acting reversible contraception. The 3D-001 product is a frameless, non-hormonal, magnetic IUD composed of three copper-encased elliptical units that self-assemble into a stable triangular configuration inside the uterus. It is delivered and removed via the company's patented i-Slider inserter and r-Slider retriever, designed to eliminate the painful insertion steps (tenaculum placement, uterine sounding, fundus contact) and dangling strings associated with traditional T-shaped IUDs.
Product overview
3Daughters is developing an integrated IUD system consisting of three core components: (1) the 3D-001 frameless, magnetic, non-hormonal copper IUD comprising three elliptical units that self-assemble into a triangular formation; (2) the i-Slider inserter for insertion; and (3) the r-Slider retriever for removal. This integrated system is designed to eliminate pain points associated with traditional T-shaped IUDs while providing contraception without hormones and without the need for dangling strings.
Differentiator
Problem solved
Functional benefit
Products and services
- 3D-001 Frameless Magnetic IUD
Quantifiable outcome
- Addresses pain during insertion reported by IUD users
- +2 more outcomes
Companies that use 3Daughters
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
3Daughters technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
3Daughters partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Parexel InternationalminorParexel participated in a BIO International Convention panel on patient-reported outcomes with 3Daughters. Nancy Kivel, MD, Senior Vice President, Global Health General Medicine and Section Head Women's Health for Parexel, joined the panel discussing patient-reported outcomes through the lens of IUD insertion pain.
- Connect Labs by Wexford (Baltimore)core3Daughters relocated headquarters to Connect Labs by Wexford within the UM BioPark. The partnership provides access to Baltimore's life sciences ecosystem including connections with University of Maryland, Baltimore, Johns Hopkins, and the entire Baltimore-Washington regional bio science corridor. Wexford's SciTech Venture Fund is both an investor and infrastructure partner.
- Dr. Carlos Gradil / University of Massachusettscore3Daughters licensed Dr. Gradil's frameless magnetic self-assembling IUD technology (iUPOD) and is applying his innovation to human contraception. Dr. Gradil serves as 3Daughters advisor and inventor. The technology was developed at UMass Amherst for veterinary use and adapted for human female anatomy.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
3Daughters competitors and assessment
Company assessmentBroad incumbents
- Bayer (Women's Health / IUD franchise): Bayer markets Mirena, Kyleena, Liletta, and Skyla — the dominant hormonal IUD franchise generating over $1B in annual revenue. Directly comparable as the incumbent 3Daughters must displace in the U.S. IUD market, with overlapping target customers (OB/GYNs) and overlapping distribution.
- Organon: Organon is a global women's health company with a portfolio spanning contraception, fertility, and menopause. Comparable as a broader women's health commercial-stage entity that 3Daughters could potentially partner with or be acquired by upon reaching late-stage clinical milestones.
- Hologic (MyoSure / Interlace Medical): Hologic acquired Interlace Medical (maker of MyoSure for fibroid/polyp removal), where 3Daughters' SVP of Manufacturing David Jacobs was VP of Operations. Comparable as a major women's health device company that 3Daughters' leadership has direct operational lineage to, and a potential strategic acquirer for women's health device assets.
Direct peers
- CooperSurgical (Paragard): CooperSurgical's Paragard is the leading non-hormonal copper IUD in the U.S. — the closest direct competitor to 3Daughters' 3D-001 copper-based product. Same patient population, same contraceptive category, same OB/GYN channel, but using the legacy T-shaped framed design.
- Sebela Women's Health (previously Juniper Pharmaceuticals): Sebela Women's Health focuses on reproductive health and contraception products including IUDs and fertility treatments. Directly comparable as a specialized women's health company targeting the OB/GYN prescribing channel for contraceptive products.
Emerging players
- Dare Bioscience: Dare Bioscience is a clinical-stage women's health company developing innovative therapies including contraception and menopause products. Comparable as a similarly sized clinical-stage women's health company navigating the FDA pathway with novel reproductive health products.
- Evofem Biosciences: Evofem developed Phexxi, a hormone-free contraceptive gel, addressing the same hormone-free contraception demand that 3Daughters targets. Comparable as a women's health company offering non-hormonal contraception to women seeking alternatives to hormonal methods.
- Agile Therapeutics: Agile Therapeutics developed Twirla, a hormonal contraceptive patch, and shares leadership lineage with 3Daughters (CEO Mary Beth Cicero was VP of Business Development at Agile). Comparable as a women's health company pursuing novel hormonal/non-hormonal contraceptive delivery.
- Mayne Pharma: Mayne Pharma has a women's health portfolio including oral contraceptives and has experience commercializing reproductive health products. Comparable as a women's health company with established distribution relationships that overlap with 3Daughters' planned OB/GYN channel.
- TherapeuticsMD: TherapeuticsMD (now part of PharmaLucent) developed hormone therapy products including the Bijuva contraceptive-adjacent therapy. Comparable as a women's health specialty company with overlapping physician customer base in OB/GYN and reproductive endocrinology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
3Daughters social profiles
Digital presence3Daughters financial estimates
Financial estimateRevenue estimate
Valuation estimate
3Daughters leadership team
Management profileNumber of profiles
Profiles17 records
3Daughters funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
3Daughters M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 3Daughters
What does 3Daughters do?
3Daughters is developing an integrated intrauterine device (IUD) system for long-acting reversible contraception. The 3D-001 product is a frameless, non-hormonal, magnetic IUD composed of three copper-encased elliptical units that self-assemble into a stable triangular configuration inside the uterus. It is delivered and removed via the company's patented i-Slider inserter and r-Slider retriever, designed to eliminate the painful insertion steps (tenaculum placement, uterine sounding, fundus contact) and dangling strings associated with traditional T-shaped IUDs.
Is 3Daughters a public or private company?
3Daughters is a private company. It is classified as venture growth investor backed and is currently operating.
When was 3Daughters founded?
3Daughters was founded in 2022. It employs 1 to 10 people.
Where is 3Daughters based?
3Daughters is headquartered in Boston, United States, in the North America region.
How does 3Daughters make money?
One revenue line is on record: IUD Product Sales.
Who are 3Daughters's main competitors?
Broad incumbents on record are Bayer (Women's Health / IUD franchise), Organon and Hologic (MyoSure / Interlace Medical). Direct peers are CooperSurgical (Paragard) and Sebela Women's Health (previously Juniper Pharmaceuticals). Emerging players are Dare Bioscience, Evofem Biosciences, Agile Therapeutics, Mayne Pharma and TherapeuticsMD.
Does 3Daughters have an API?
No public API is recorded for 3Daughters.
What industry is 3Daughters in?
3Daughters's product category is Contraceptive Medical Devices. Its primary akta.pro industry code is HLAKAJAF, Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy). Its NAICS code is 339113 and its SIC code is 3841.